Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631

PURPOSE: The Children’s Oncology Group AAML0631 trial for newly diagnosed pediatric acute promyelocytic leukemia (APL) was a phase III historically controlled trial to determine the survival of patients receiving arsenic trioxide (ATO) consolidation and reduced doses of anthracyclines. PATIENTS AND...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Kutny, Matthew A., Alonzo, Todd A., Gerbing, Robert B., Wang, Yi-Cheng, Raimondi, Susana C., Hirsch, Betsy A., Fu, Cecilia H., Meshinchi, Soheil, Gamis, Alan S., Feusner, James H., Gregory, John J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2017
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5590801/
https://ncbi.nlm.nih.gov/pubmed/28767288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.6183
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi